Abstracts

686 – Implementation of LA-CAB/RPV in US Clinic Settings: A Survey of Front-Line Clinicians

Background Long-acting Cabotegravir and Rilpivirine (LA-CAB/RPV), approved in January 2021, is the first complete injectable regimen for virologically suppressed patients with HIV-1 without a history of resistance. The availability of LA-CAB/RPV offers a significant opportunity to expand the landscape of care for people with HIV. However, data on its implementation outside of early phase clinical…

687 – Distance to Care Measures Predict Injection Visit No-Shows Among Cabotegravir/Rilpivirine Recipients

Background Various distance to care (DTC) measures exist. It is unclear which most accurately predicts injection visit adherence for persons with HIV receiving long acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV). Objectives were to: i) identify which DTC measures were associated with injection visit no-shows (IVNS) and ii) compare the strength of association of each DTC measure…

761 – Incidence and Impact of Hepatic Steatosis in People With HIV: Insights From the NA-ACCORD Cohort

Background Hepatic steatosis is an increasingly important comorbidity in aging people with HIV (PWH). Population-representative estimates of incidence, risk factors and association with liver-related events are not well understood. We evaluated the incidence of hepatic steatosis and its association with liver-related events and overall mortality within the NA-ACCORD. Methods Hepatic steatosis was defined using the…

637 – Incidence and Risk Factors for Neurocognitive Disorders Among Persons With HIV in Washington, DC

Background Development of neurocognitive disorders (ND) remains a concern among persons with HIV (PWH), despite advances in antiretroviral treatments (ART) which have aided in reducing ND incidence. Studies have indicated increased risk for ND among PWH with comorbidities such as obesity, cardiovascular disease (CVD), Hepatitis C, and toxoplasmosis. The purpose of this analysis was to…

572 – HIV Proviral Populations Differ by Sex and Immune Activation Levels During Antiretroviral Therapy

Background Understanding mechanisms driving persistence and clonal expansion of HIV infected cells during antiretroviral therapy (ART) is critical to control of HIV.  Most infected cells contain proviruses that are defective for replication, but can express RNA and HIV proteins, including Gag, that may contribute to pathogenesis on ART. Roles of sex, age, and immune status…

590 – Evaluating White Matter Integrity in Relation to HIV Severity and Cognitive Impairment

Background Though incurable, HIV has become widely treatable with combination antiretroviral therapy (cART), significantly extending the lifespan of people living with HIV (PLWH). This has resulted in an aging PLWH population facing growing concerns for age-associated HIV comorbidities such as cognitive impairment (CI), which remains equally prevalent and relevant for PLWH in the cART era.…

486 – Consecutive Analytical Treatment Interruption Improves CD8 T-Cell Activity During Viral Control

Background In the PULSE clinical trial, 68 people living with HIV underwent three consecutive analytical treatment interruptions (ATIs). Of note, 10% of the participants transiently controlled HIV rebound during the 3rd ATI. We investigated whether this virological control is associated with improved antiviral CD8 T-cell function and response to mutationally-constrained and highly-conserved HIV epitopes. Methods…